OR WAIT null SECS
Through the acquisition, PharmaLex will expand its capabilities in the biopharma sector while enhancing its global market reach with a new location in Australia.
PharmaLex, a provider of specialized services for the pharma, biotech, and medtech industries, announced on Feb. 24, 2021 that it has completed its acquisition of ERA Consulting, a consulting firm that provides product development and regulatory support.
Through the acquisition, PharmaLex will expand its capabilities in the biopharma sector while enhancing its global market reach with a new location in Australia, PharmaLex said in a company press release.
“The ERA team is excited about being part of the PharmaLex Group, as this enables us to provide additional support to our clients through the breadth of PharmaLex’s services,” said Andrew Moore, chief operating officer, ERA, in the press release.
“The addition of ERA to the PharmaLex Group represents a key milestone in the company’s strategic orientation as solution provider for the biotech sector. ERA’s extensive expertise will add significant value to further build our biopharma solutions,” added Dr. Thomas Dobmeyer, CEO, PharmaLex, in the press release. “Expanding our global network into Australia is also an important step and will help us strengthen our Asia-Pacific reach.”